Ahead of Robert F. Kennedy Jr.’s confirmation hearings, experts—and RFK’s own family—expressed concerns about his ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

In two new papers, researchers from The Jackson Laboratory (JAX) report the successful use of two approaches -- gene therapy ...

UC San Diego announced that it is offering a newly Food and Drug Administration-approved gene therapy for hemophilia B, a ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

We can do better. We can build a system that provides coordinated high-quality care to every patient who needs it.

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...